Blockade of the CD40–CD40L and CD80/CD86–CD28 costimulatory pathways represents a strategy to inhibit the immune response against Ad vectors designed for gene therapy applications. Since most ...

The crucial role of costimulatory molecules, CD28, CTLA-4, CD80 and CD86, for T cell activation and inhibition has been established. In the previous study, we reported the results of a ...

There are currently seven known members of this family of ligands. The most well-known are B7-1 (CD80) and B7-2 (CD86), which interact with CD28 and CTLA-4 to regulate T cell signaling.

CD28 serves as the receptor for CD80 (B7.1) and CD86 (B7.2). When antigen-presenting cells (APCs) are activated by Toll-like receptor ligands, CD80 expression is upregulated, while CD86 expression ...

CD28 and ICOS are expressed on T cells, interacting with CD80/CD86 and ICOS ligand (ICOSL), respectively, and play critical roles in T cell activation.

PD-1 is now recognized to effect much of its benefit by disinhibiting CD28 signaling – a mechanism expected to require intra-tumoral engagement of CD28 by its ligands CD80/CD86. Davoceticept (ALPN-202 ...

FPT155 is not an antibody, but a CD80-Fc fusion protein. CD80 is a co-stimulatory ligand of CD28, which is the dominant co-stimulatory pathway by which T-cells are activated.

"Our data suggest that the CD80/CD86-CD28 axis may be exploited in the design of pediatric vaccines to promote the generation of more "adult-like" immune responses." ...

Manipulating the CD80/CD86 pathway may yield new strategies for treating multiple myeloma, new research on dendritic cells suggests. This research focused on the immune system’s dendritic cells ...

In addition to binding the CD80 and CD86 receptors on the surface of antigen presenting cells, impairing their ability to activate T cells, the CTLA-4 receptor on T helper cells can physically snatch ...